Looking For The Best Biotech Stocks to Watch In January? 3 Names To Know
Biotech stocks have been one of the top-performing industries in the last few months. With the coronavirus spreading like wildfire, it is no surprise that biotech companies were at the frontlines in creating a vaccine. Investors looking for high returns could always turn to biotech stocks. This is because the biotech industry is full of clinical-stage companies that can explode in value overnight. Biotech company Moderna (MRNA Stock Report) has just had its vaccine approved in the U.K. today. Another instance would be Crispr Therapeutics (CRSP Stock Report) that has just seen its share price increase by over 20% since Thursdayâs opening bell.
Coldwater, MI, USA / WTVB | 1590 AM · 95.5 FM | The Voice of Branch County
Jan 6, 2021 7:39 AM
(Reuters) - The European Union s drug watchdog on Wednesday authorized emergency use of Moderna Inc s COVID-19 vaccine, nearly two weeks after approving Pfizer Inc and BioNTech SE s shot for the virus.
On Tuesday, Israel became the first country outside North America to grant authorization to Moderna s vaccine. The United States and Canada have already started rolling out the two-dose vaccine.
Below are more details on Moderna s vaccine:
VACCINE TECHNOLOGY
- The vaccine, called mRNA-1273, is based on messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines.
The best stock picker of 2020 wins with disruptive DNA
Matthew A. Winkler, Bloomberg News
What worked in 2020 likely won t work in 2021: Mike O Rourke VIDEO SIGN OUT
Everyone should know Cathie Wood by now.
That s because whatever benefits central bankers bequeathed to shareholders with next-to-zero interest rates and the record US$14 trillion global money supply increase in 2020, Wood beat every stock picker by betting on the innovators in DNA development who are rescuing the world from the global pandemic.
Among the 367 U.S.-based mutual funds with 60 per cent of their US$5 billion (or more) in American equities, her ARK Genomic Revolution ETF, ARK Innovation ETF and ARK Next Generation Internet ETF are far ahead, reaping bonanzas of 203 per cent, 159 per cent and 157 per cent, respectively.